My ePortfolio Register   

New editorial - does the oncology community have a rejection bias when it comes to repurposed drugs?

In a new editorial by ecancermedicalscience Editorial Board member Dr Bishal Gyawali, three examples of low-priced drugs which were rejected or ignored by the oncology community are contrasted with three expensive drugs where persistent optimism remained despite negative clinical trial results.

Dr Gyawali maintains that  all drugs should be held to the same rigorous standards – this not only includes skepticism in the absence of sound evidence, but also the suspension of premature judgement as has happened in the cases of repurposed drugs.

Read the full editorial here.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence